| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725074 | Clinical Gastroenterology and Hepatology | 2018 | 46 Pages |
Abstract
By using the MISCAN-Colon microsimulation model to estimate effects of CRC screening tests, we found that for a biomarker test with increased overall performance to be cost-effective, it should not exceed 7-fold the unit cost of FIT. This maximum would increase substantially if colonoscopy becomes more expensive or scarce, or if the new test has higher screening uptake. These values could be used to estimate the added value of new biomarkers compared with current FIT screening.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Iris Lansdorp-Vogelaar, S. Lucas Goede, Linda J.W. Bosch, Veerle Melotte, Beatriz Carvalho, Manon van Engeland, Gerrit A. Meijer, Harry J. de Koning, Marjolein van Ballegooijen,